Ovarian Cancer Market to Grow Rapidly at a CAGR of 16% by 2030 | DataM Intelligence
04 août 2023 11h00 HE
|
DataM Intelligence
New York, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The Global Ovarian Cancer Market is estimated to grow at a CAGR of 16% during the forecast period (2023-2030). Ovarian cancer is a significant public...
IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
03 août 2023 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Gemcitabine HCL Market to Achieve CAGR of 7.4%, Exceeding US$ 1.3 Bn by 2031
26 juil. 2023 09h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, July 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The gemcitabine HCL market was valued at US$ 635.1 Mn in 2021 and is projected to exceed...
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
20 juil. 2023 11h45 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the...
Oncology Biomarkers Global Market to 2028: Increased Availability and Ease of Biomarker Testing Fuels the Sector
04 juil. 2023 05h13 HE
|
Research and Markets
Dublin, July 04, 2023 (GLOBE NEWSWIRE) -- The "Oncology Biomarkers: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global oncology biomarkers market reached a...
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
22 juin 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the...
Genelux Corporation Announces $18 Million Private Placement
12 juin 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares...
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
24 mai 2023 16h05 HE
|
Myriad Genetics, Inc.
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a...
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
15 mai 2023 08h45 HE
|
AIM ImmunoTech Inc.
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023– Lead clinical program, Phase 2 locally advance pancreatic...
Genelux Corporation Announces $33 Million Private Placement
15 mai 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares...